Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

Instituto Mexicano del Seguro Social

Status: Completed

Conditions: Multiple Myeloma

Treatments: Drug: zoledronic acid

Study type: Observational

Funder types: Other

Identifiers

NCT01234129

kitty1

kitty2 (Other Identifier)

Details and patient eligibility

About

Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.

Full description

Assess if the use of zoledronic acid can improve outcome in patients with multiple myeloma whose are treated with cytoreductive therapy and stem cell transplant.

Enrollment: 320 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Diagnosis of multiple myeloma No previous treatment Symptomatic High risk (ISS) or stage III ( Durie-Salmon) No severe comorbidities -

Exclusion criteria

Pregnancy HIV + Refuse treatment

Trial design

320 participants in 2 patient groups

zoledronic acid or not zoledronic acid

Description:

patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid

Treatment:

Drug: zoledronic acid

zoledronic acid

Description:

Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid

Treatment:

Drug: zoledronic acid